Hamamatsu Photonics K.K. (HPK) is a Japanese optoelectronics manufacturer headquartered in Hamamatsu City, Japan (Nihon Seimei Hamamatsu Ekimae Bldg., Naka-ku). Founded September 29, 1953 as Hamamatsu TV Co. and renamed in 1983, it is publicly listed on the Tokyo Stock Exchange Prime Market (code 6965). It is not a subsidiary. Consolidated headcount is roughly 6,600, about 4,262 of them in Japan; consolidated net sales were ¥212.0 billion for the fiscal year ended September 30, 2025 (about $1.4 billion), with R&D at 8.7% of sales.
Products/operations. HPK develops and sells optical devices and systems across four segments: Electron Tube (photomultiplier tubes, imaging devices, light sources); Optoelectronic Semiconductor (photodiodes, APDs, MPPC/SiPM, CCD/CMOS and InGaAs image sensors); Image Processing and Measurement Equipment (scientific cameras such as the ORCA series, spectrometers, measurement systems); and Laser (laser equipment and components). It claims roughly 90% global share in high-sensitivity photomultiplier tubes and sells into medical, analytical, industrial, semiconductor, and academic markets. It acquired Denmark's NKT Photonics in 2024 (now the Lasers & Fibers business unit) and Fairchild Imaging. It is an operating company, not a patent assertion entity.
Litigation posture. The tracked data show one case, with HPK as defendant and zero as plaintiff — the profile of an operating company being sued rather than an active enforcer. The single suit sits in the U.S. District Court for the District of Massachusetts, not a plaintiff-friendly venue such as the Eastern District of Texas.
Notable case. SiOnyx, LLC and President and Fellows of Harvard College v. Hamamatsu Photonics K.K., Hamamatsu Corp., and Ocean Optics, Inc. (No. 1:15-cv-13488, filed October 1, 2015, Judge F. Dennis Saylor IV). It concerned laser-textured "black silicon" silicon photodetectors and combined patent-infringement, correction-of-inventorship, and breach-of-NDA claims. Public dockets and opinions record a jury verdict for SiOnyx, post-trial injunctive relief, and a Federal Circuit appeal; no merits view is expressed here.